UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000023899
Receipt number R000027524
Scientific Title The efficacy of bifidobacterium preparation LKM512 for rectal aberrant crypt foci: A double-blind randomized controlled trial
Date of disclosure of the study information 2016/09/01
Last modified on 2019/03/13 22:37:46

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The efficacy of bifidobacterium preparation LKM512 for rectal aberrant crypt foci: A double-blind randomized controlled trial

Acronym

LKM512 for rectal ACF

Scientific Title

The efficacy of bifidobacterium preparation LKM512 for rectal aberrant crypt foci: A double-blind randomized controlled trial

Scientific Title:Acronym

LKM512 for rectal ACF

Region

Japan


Condition

Condition

Patients with both resectable colorectal adenoma/carcinoma in situ by colonoscopy and rectal ACF

Classification by specialty

Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To analyze the efficaty of Bifidobacterium preparation LKM512 for rectal aberranty crypt foci

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II,III


Assessment

Primary outcomes

The amount of change of rectal ACF

Key secondary outcomes

The change of microbiota
Safety
The cell-proliferative and apoptotic activities in the colorectal epithelium and adenoma/cancer


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

YES

Dynamic allocation

NO

Institution consideration

Institution is considered as a block.

Blocking

YES

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Medicine Food

Interventions/Control_1

receive oral LKM512 powder 1g per day for 2 month

Interventions/Control_2

receive oral placebo powder per day for 2 month

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

40 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

1.Patients with both colorectal ACF and resectable adenoma/cancer.
2.Willingness to provide written informed consent

Key exclusion criteria

1.History of regular use of Lactobacillous, Bifidobacterium preparation supplements.
2.History of regular use (defined as at least once per week) of NSAIDs and/or aspirin.
3.History of heart failure, renal failure, liver cirrhosis or chronic hepatic failure
4.History of familial adenomatous polyposis
5.History of hereditary non-polyposis colorectal cancer
6.History of inflammatory bowel disease
7.Pregnancy or possibility of pregnancy
8.Patients judged as inappropriate candidates for the trial by the investigators

Target sample size

60


Research contact person

Name of lead principal investigator

1st name Takuma
Middle name
Last name Higurashi

Organization

Yokohama City Univesity

Division name

Department of Gastroenterology and Hepatology

Zip code

236-0004

Address

3-9 Fukuura Kanazawa-ku Yokohama City

TEL

045-787-2640

Email

takuma_h@yokohama-cu.ac.jp


Public contact

Name of contact person

1st name Takuma
Middle name
Last name Higurashi

Organization

Yokohama City Univesity

Division name

Department of Gastroenterology and Hepatology

Zip code

236-0004

Address

3-9 Fukuura Kanazawa-ku Yokohama City

TEL

045-787-2640

Homepage URL


Email

takuma_h@yokohama-cu.ac.jp


Sponsor or person

Institute

Yokohama City Univesity

Institute

Department

Personal name



Funding Source

Organization

(WAKATE-B) from the Ministry of Health, Labour and Welfare, Japan

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Yokohama City University Hospital IRB

Address

3-9 Fukuura Kanazawa-ku Yokohama City

Tel

81-45-787-2640

Email

takuma_h@yokohama-cu.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 09 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2016 Year 07 Month 01 Day

Date of IRB

2016 Year 08 Month 31 Day

Anticipated trial start date

2016 Year 09 Month 01 Day

Last follow-up date

2019 Year 12 Month 31 Day

Date of closure to data entry

2020 Year 01 Month 31 Day

Date trial data considered complete

2020 Year 02 Month 28 Day

Date analysis concluded

2020 Year 03 Month 31 Day


Other

Other related information



Management information

Registered date

2016 Year 09 Month 01 Day

Last modified on

2019 Year 03 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027524


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name